PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-177.89%
Both yoy net incomes decline, with CRK at -70.99%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
15.71%
Less D&A growth vs. CRK's 135.78%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
68.72%
Some yoy growth while CRK is negative at -21564.37%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-8.20%
Both cut yoy SBC, with CRK at -10.49%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-163.27%
Negative yoy working capital usage while CRK is 1417.68%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
-164.71%
Both yoy AR lines negative, with CRK at -81.96%. Martin Whitman would suspect an overall sector lean approach or softer demand.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-78.79%
Negative yoy usage while CRK is 843.95%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-3.45%
Both negative yoy, with CRK at -9.25%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
3.36%
Operating cash flow growth below 50% of CRK's 137.89%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
-7.61%
Both yoy lines negative, with CRK at -2.84%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-96.47%
Negative yoy acquisition while CRK stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
7.61%
Purchases growth of 7.61% while CRK is zero at 0.00%. Bruce Berkowitz sees a mild difference in portfolio building that might matter for returns.
-214.29%
We reduce yoy sales while CRK is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
-7.61%
Both yoy lines negative, with CRK at -18274.93%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-406.71%
Both yoy lines negative, with CRK at -6.32%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.